Form 4: Denali Therapeutics Director Peter S. Klein Granted Equity Awards

Denali Therapeutics Inc. Director Peter S. Klein was granted 6,037 Restricted Stock Units and options to purchase 18,111 shares of common stock on June 3, 2025, as part of his compensation.

Summary

• Peter S. Klein, a Director of Denali Therapeutics Inc. (DNLI), was granted equity awards on June 3, 2025.
• He acquired 6,037 Restricted Stock Units (RSUs) at a grant price of $0. Each RSU represents a contingent right to receive one share of common stock.
• These RSUs will vest 100% upon the earlier of (i) the one-year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
• Following this transaction, Mr. Klein beneficially owns 27,533 shares of common stock, which includes the 6,037 unvested RSUs.
• Additionally, Mr. Klein was granted stock options to purchase 18,111 shares of common stock with an exercise price of $13.93 per share.
• These stock options also vest 100% upon the earlier of (i) the one-year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
• The options have an expiration date of June 3, 2035.
• Following this transaction, Mr. Klein beneficially owns 18,111 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally a positive or neutral event, aligning interests and serving as a standard compensation practice. It indicates continued commitment from the director.

Positives

• The grant of equity awards to Director Peter S. Klein aligns his interests with those of shareholders, incentivizing long-term company performance.
• Equity compensation is a common and effective way to attract and retain experienced board members.

Negatives

• The issuance of new equity awards can lead to minor dilution for existing shareholders, although the amount in this filing is relatively small.

Risks

• The value of the granted RSUs and stock options is tied to the future performance of Denali Therapeutics' stock price, meaning their ultimate value to Mr. Klein is not guaranteed.
• The vesting conditions require continued service, and if Mr. Klein ceases to be a director before vesting, the unvested awards may be forfeited.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction, beyond the vesting schedule of the granted equity awards.

Industry Context

The granting of equity compensation to directors is a standard practice across the biotechnology and pharmaceutical industries, aiming to align leadership incentives with long-term shareholder value creation. Denali Therapeutics, as a biopharmaceutical company, utilizes such compensation structures to attract and retain top talent in a competitive sector.

Comparison to Industry Standards

• The compensation structure, involving a mix of Restricted Stock Units and stock options with a one-year vesting period or vesting upon the next annual meeting, is consistent with common practices for non-employee directors in the U.S. biotechnology industry.
• While specific grant sizes vary by company size and individual director responsibilities, the general approach aligns with benchmarks seen at comparable biopharmaceutical firms.

Related Party Transactions

• The transaction involves the grant of equity compensation to Peter S. Klein, a Director of Denali Therapeutics Inc., which is a standard related-party transaction for director compensation.

Stakeholder Impact

• Shareholders: Potential minor dilution from the issuance of new shares upon RSU vesting and option exercise, but also improved alignment of director interests with shareholder value.

Next Steps

• The granted Restricted Stock Units and stock options will vest upon the earlier of the one-year anniversary of the grant date (June 3, 2025) or the day preceding Denali Therapeutics' next annual meeting of stockholders.
• Upon vesting, the RSUs will convert into common stock, and the stock options will become exercisable.

Key Dates

Keywords

Denali Therapeutics, DNLI, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSU, Stock Options, Director Compensation, Peter S. Klein, Beneficial Ownership